SecBot SecBot
SECBOTREPLAY Home › Report › IBRX

IBRX · ImmunityBio submitted a comprehensive response to an FDA warning letter…

ImmunityBio, Inc. · 8-K filed Apr 6, 2026 at 08:03 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Apr 6, 2026 at 08:03 ET

ImmunityBio submitted a comprehensive response to an FDA warning letter regarding promotional materials for its drug ANKTIVA, confirming a cited television ad was never aired and removing a podcast under review. The company is implementing enhanced compliance measures, including executive training and external oversight.

  • FDA issued a Warning Letter on March 13, 2026, concerning promotional materials for ANKTIVA.
  • ImmunityBio confirmed the cited television advertisement was never broadcast or disseminated.
  • The company removed the identified podcast from its website and requested removal from third-party platforms.
  • Corrective actions include mandatory executive training, expanded Promotional Review Committee (PRC) protocols, and engagement of external regulatory counsel.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access